Zentalis Pharmaceuticals, Inc.
Close on Oct 19, 2026
- Market cap
- $164.05M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 9, 2026, after market close (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 6, 2026 | After market close | – | – | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 12, 2026 | After market close | – | $-0.50 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 26, 2026 | After market close | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 10, 2025 | After market close | – | $-0.37 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 6, 2025 | After market close | – | $-0.37 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 14, 2025 | After market close | – | $-0.67 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 26, 2025 | After market close | – | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 9, 2024 | Before market open | – | $-1.24 | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 7, 2024 | Before market open | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Feb 27, 2024 | Before market open | – | – | – |
| Q3 FY2023 Ended Sep 30, 2023 | Nov 6, 2023 | Before market open | – | – | – |
Press releases
Announcements Zentalis Pharmaceuticals filed with the SEC
Zentalis Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Updates
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Pioneering WEE1 Inhibition to Deliver More Convenient, Targeted Cancer Care Corporate Presentation | August 2026 Nasdaq: ZNTL
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Zentalis Pharmaceuticals to Present Phase 1b MUIR Trial Data Showing Encouraging Clinical Activity and Manageable Safety Profile of Azenosertib Plus Paclitaxel in Platinum-Resistant Ovarian Cancer at ASCO 2026
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Zentalis Pharmaceuticals Reports First Quarter 2026 Financial Results and Clinical Progress
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Pioneering WEE1 Inhibition to Deliver More Convenient, Targeted Cancer Care Corporate Presentation | May 2026 Nasdaq: ZNTL
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Zentalis Pharmaceuticals Announces First Patient Dosed in ASPENOVA Phase 3 Trial of Azenosertib in Patients with Cyclin E1-Positive Platinum-Resistant Ovarian Cancer
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Regulation FD disclosure · EX-99.2 to Form 8-K
EX-99.3 to Form 8-K
Regulation FD disclosure · EX-99.3 to Form 8-K
Corporate Presentation April 2026 Nasdaq: ZNTL
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Zentalis Pharmaceuticals Announces 400mg QD 5:2 Azenosertib Monotherapy as the Pivotal Study Dose in Cyclin E1-Positive Platinum-Resistant Ovarian Cancer
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Zentalis Pharmaceuticals Reports Full Year 2025 Financial Results and Operational Updates
Results of operations · EX-99.1 to Form 8-K
Corporate Presentation January 2026 Nasdaq: ZNTL
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Zentalis Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operational Progress
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Corporate Presentation November 2025 Nasdaq: ZNTL
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Zentalis Pharmaceuticals Appoints James B. Bucher, JD, as Chief Legal Officer and Corporate Secretary
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Zentalis Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational Progress
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Corporate Presentation August 2025 Nasdaq: ZNTL
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Zentalis Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Progress
Results of operations · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Regulation FD disclosure · EX-99.2 to Form 8-K
EX-99.3 to Form 8-K
Regulation FD disclosure · EX-99.3 to Form 8-K
Zentalis Pharmaceuticals Reports Full Year 2024 Financial Results and Operational Updates
Results of operations · EX-99.1 to Form 8-K
Zentalis Pharmaceuticals Presents Updated Clinical Data at the Society of Gynecologic Oncology 2025 Annual Meeting on Women’s Cancer
Regulation FD disclosure · EX-99.1 to Form 8-K
I will be discussing the unlabeled or investigational use of Azenosertib, a WEE1 inhibitor, from Zentalis Pharmaceuticals Unlabeled/Investigational Uses
Regulation FD disclosure · EX-99.2 to Form 8-K
Zentalis Pharmaceuticals Shares Updated Clinical Data Demonstrating Meaningful Azenosertib Activity in Cyclin E1+, Platinum-Resistant Ovarian Cancer
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Corporate Event January 29, 2025 Nasdaq: ZNTL Exhibit 99.2
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Zentalis Pharmaceuticals Announces Strategic Restructuring to Support Late-Stage Azenosertib Development
Exit or restructuring costs · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Zentalis Pharmaceuticals Announces Executive Leadership Changes Supporting Planned Registrational Clinical Studies of Azenosertib
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Zentalis Pharmaceuticals Announces FDA Has Lifted Partial Clinical Hold on Azenosertib Studies
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Zentalis Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operational Progress
Results of operations · EX-99.1 to Form 8-K
Corporate Presentation Nasdaq: ZNTL June 2024 Exhibit 99.1
Regulation FD disclosure · EX-99.1 to Form 8-K
Zentalis Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Progress
Results of operations · EX-99.1 to Form 8-K
Corporate Presentation Nasdaq: ZNTL April 2024 Exhibit 99.1
Regulation FD disclosure · EX-99.1 to Form 8-K
Zentalis Pharmaceuticals Reports Full Year 2023 Financial Results and Operational Updates
Results of operations · EX-99.1 to Form 8-K
Zentalis Pharmaceuticals Strengthens Management Team with Key Appointments
Listing notice · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Immunome Exclusively Licenses Zentalis ROR1 Antibody-Drug Conjugate and Proprietary Technology Platform
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Zentalis Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operational Updates
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Corporate Presentation Nasdaq: ZNTL November 2023 Exhibit 99.2
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K